Calder Biosciences is a vaccine immunogen design company that is developing novel RSV and universal Influenza subunit vaccines, both representing $ multi-billion market opportunities with mitigated clinical risk. We apply our patented, nano-scale, targeted crosslinking technology to lock key viral proteins in the conformation that best elicits protective antibody responses and in so doing, also improve the thermo-stability and shelf life of the resulting vaccine immunogens.
Our targeted, di-tyrosine crosslinking platform technology is robust and versatile and we are able to quickly design and generate vaccine candidates with significant commercial potential and with proprietary composition of matter IP. Calder has a favorable risk/reward profile because we do not perform de novo discovery, but rather engineer solutions to well-characterized problems that are uniquely addressable with our DT conformational locking technology.
Read more about Calder's Team.
Read more about Calder's Intellectual Property.
Our targeted, di-tyrosine crosslinking platform technology is robust and versatile and we are able to quickly design and generate vaccine candidates with significant commercial potential and with proprietary composition of matter IP. Calder has a favorable risk/reward profile because we do not perform de novo discovery, but rather engineer solutions to well-characterized problems that are uniquely addressable with our DT conformational locking technology.
Read more about Calder's Team.
Read more about Calder's Intellectual Property.